[UPDATE 27/05/2015]: Sorin’ shareholders approved the merger with Cyberonics in an Extraordinary Meeting.

Sorin and Cyberonics, agreed on a merger plan to create a new global leader in medical technologies with a combined equity value of approximately €2.4Bn based on the closing price of Sorin and Cyberonics shares of 25th February.

Sorin and Cyberonics will combine under a newly formed holding company, “NewCo”, which the parties will name prior to closing. Each Cyberonics stockholder will receive one ordinary share of NewCo for every share of Cyberonics owned. Furthermore, each Sorin shareholder will receive a fixed ratio of 0.0472 ordinary shares of NewCo for every Sorin share owned. Sorin shareholders will own approximately 46% of NewCo, and Cyberonics shareholders will own approximately 54%, on a fully diluted basis.

ADVERTISEMENT

The proposed transaction, the second-largest US-Europe deal so far this year, will bring together global leaders from the in cardiac surgery and neuromodulation sectors, and the combined company will also be a major player in cardiac rhythm management, especially in Europe and Japan. NewCo will have several promising opportunities focused on multi-billion dollar markets, in particular, on three product categories: heart failure, sleep apnea and percutaneous mitral valve.

Regarding heart failure, NewCo will have promising products with European market entry starting as early as 2015. Cyberonics recently received CE Mark approval of its VITARIA device delivering autonomic regulation therapy for the treatment of chronic heart failure and will commence a limited market launch in Europe in the coming weeks. Recently, Sorin announced the first successful implants of its Equilia Vagus Nerve Stimulation system for heart failure patients. NewCo is expected to benefit from the developing market for active implantable treatments for sleep apnea with investments, recently launched in selected European countries, destined to the under-addressed obstructive sleep apnea (OSA) market, and also to central sleep apnea (CSA). In addition, NewCo is expected to have new percutaneous mitral valve replacement/repair products with estimated initial market entries by 2017.

André-Michel Ballester, Chief Executive Officer of Sorin, will serve as Chief Executive Officer of NewCo, whereas Dan Moore, Chief Executive Officer of Cyberonics, will become non-executive Chairman.

Andre-Michel_Ballester_Sorin

Commenting on the announcement, André-Michel Ballester stated: “I am delighted to announce this transformational merger between Sorin and Cyberonics. As one company we will be able to leverage our combined strengths, capture new opportunities and create new solutions to benefit patients and healthcare professionals alike. This is particularly exciting for our employees, who will be able to share technical expertise and innovate faster, ensuring that we serve our customers by remaining at the forefront of new product development which continues to be the foundation of our success.

The Texas-based company Cyberonics will move to London, which will signify an important tax reduction, as UK corporate taxes only lie by 21% compared to the 35% rate in the US. The Cyberonics-Sorin combination will have a strategic presence in over 100 countries, where they will focus on their innovation platform to exploit market opportunities and accelerate product development.

Previous post

Amgen dumps suicidal-related AstraZeneca’s psoriasis project

Next post

Qiagen offers a powerful bioinformatics tool for Next-gen sequencing

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.